CClinicalTrials.gg
CompletedNCT04340323PELSTABUpdated Mar 2, 2022

The Effect of Pelvic Floor Muscle Training With Stabilization Exercises With Various Intensity in Women With Stress Urinary Incontinence

An interventional study of Pelvic Floor Muscle Training (PFMT) in Stress Urinary Incontinence, sponsored by Pavol Jozef Safarik University. Completed at 1 site in Slovakia. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Pavol Jozef Safarik University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Study summary

This study will evaluate the safety, tolerability and efficacy of high- and low-intensity PFMT with stabilization exercises in women with SUI

Read the detailed description

This is a randomized interventional parallel study to evaluate the effect of PFMT with stabilization exercises of high and low intensity in women with SUI

02

Conditions studied

  • Stress Urinary Incontinence

Keywords

  • Stress urinary incontinence;
  • 2D/3D ultrasound
  • Pelvic floor muscle training
03

In context

Urinary Incontinence

1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.

This study's enrollment of 86 is above the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Pavol Jozef Safarik University is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Willing to provide written informed consent
  2. Over 18 years old and experiencing uncomplicated SUI
  3. Score on the International Consultation on Urinary Incontinence Questionnaire of ≥ 6 points
  4. Symptoms of urinary incontinence for at least three consecutive months
  5. Degree of pelvic organ prolapse, stage ≤ 2
  6. Willingness to accept the randomization process and fully participate in tests

Exclusion criteria

Exclusion Criteria:

  1. History of anti-incontinence surgery in the past 12 months
  2. History of pelvic prolapse repair or urethral surgery in the past 12 months
  3. History of PFMT in the past 12 months
  4. History of interstitial cystitis or bladder-related pain
  5. Chronic severe constipation
  6. Clinically significant renal or hepatic impairment
  7. Clinically significant heart impairment
  8. Pregnant, lactating or actively trying to become pregnant
  9. Positive urinary tract infection
  10. Use of rehabilitation aids (pessaries, urethral plugs, vaginal beads, etc.)
  11. Insufficient understanding of pelvic floor exercises and/or omitting exercises
  12. Incomplete questionnaire
  13. Refusal to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Group A-intensive exercise group

    Dosage of intensive exercise group - 12 weeks, five times a week for 30 minutes per day; five times with education by a physiotherapist, followed by continuation at home. PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist. 1. Educating probands about anatomy, physiology and pelvic floor muscle function. 2. Training of pelvic floor muscles in different positions. 3. Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles.

    Other: Pelvic Floor Muscle Training (PFMT)

  • Active comparator
    Group B-low-intensity exercise group

    Dosage of low-intensity exercise group - 12 weeks, twice a week for 15 minutes per day; five times with physiotherapist education, followed by continuation at home. PFMT with lumbopelvic stabilization. Exercise up to five times a week for up to 30 minutes per day, after initial training with a physiotherapist. 1. Educating probands about anatomy, physiology and pelvic floor muscle function. 2. Training of pelvic floor muscles in different positions. 3. Training of pelvic floor muscles with six stabilization exercises - activation of deep trunk muscles.

    Other: Pelvic Floor Muscle Training (PFMT)

Interventions

  • OtherPelvic Floor Muscle Training (PFMT)

    The method of first choice in SUI treatment according to the International Continence Society (ICS) is training of the pelvic floor muscles. Pelvic floor muscle training (PFMT) is a method based on scientific evidence, defined by the ICS as repeated selective voluntary contraction and relaxation of specific pelvic floor muscles. It is important to train the strength and endurance of the pelvic floor muscles but also their relaxation (Abrams, 2018; Arnold, 2014; Bo, 2013).

06

What researchers measure

Primary outcomes

  1. Change in incontinence episode frequency (IEF) over one week.

    Change in the number of urinary leakages during the day, measured by the voiding diary.

    Time frame: change in incontinence episode frequency over 12 weeks of treatment

Secondary outcomes

  1. Change in performance and endurance of pelvic floor muscles

    Performance on five-degree scale of 0-5 is used (no contraction, weak contraction, normal contraction, strong contraction, very strong contraction). Endurance - the patient is requested to perform a maximum voluntary contraction of the pelvic floor and the contraction weakening time is measured. Time is given in seconds, for a maximum of 10 seconds.

    Time frame: Change in performance and endurance of pelvic floor muscles over 12 weeks of treatment

  2. Change in hiatal area (HA, in cm2) during the Valsalva manoeuvre, assessed by 3D ultrasound

    Examination will be carried out using a ultrasound console, volume contrast imaging software and a 3D/4D 4-8 MHz probe in the midsagittal plane. Examination will take place with an empty bladder in the lithotomy position. The probe will be placed longitudinally on the perineum. A 3D image will be taken at rest, at maximum contraction and at the Valsalva manoeuvre. The amount of hiatial space at the Valsalva manoeuvre will be measured in cm2.

    Time frame: Change in hiatal area (HA, in cm2) during the Valsalva manoeuvre, assessed by 3D ultrasound over 12 weeks of treatment

  3. Change in incontinence quality of life

    Urinary Incontinence Quality of Life Scale (I-QoL) The I-QoL is composed of three subscales (avoidance and limiting behaviour; psychosocial impact; social embarrassment) and comprises 22 questions with a total score in the range from 0 (worst quality of life) to 100 (best quality of life).

    Time frame: Change in incontinence quality of life over 12 weeks of treatment

  4. Change in patient global impression

    Patient Global Impression of Improvement Scale (PGI-I) The PGI-I evaluates the status of urination problems compared to the patient's condition before treatment in the study. Patient impressions are evaluated according to the following scores: 1, much better; 2, quite better; 3, a little better; 4, no change; 5, a little worse; 6, a lot worse; 7, definitely worse.

    Time frame: Change in patient global impression over 12 weeks of treatment

07

Study locations

1 site
  • Pavol Jozef Safarik University, Faculty of Medicine
    Kosice, 04001, Slovakia
08

References and documents

Publications

  • Hagovska M, Urdzik P, Svihra J. A randomized interventional parallel study to evaluate the effect of pelvic floor muscle training with stabilization exercises of high and low intensity in women with stress urinary incontinence: The PELSTAB study. Medicine (Baltimore). 2020 Jul 17;99(29):e21264. doi: 10.1097/MD.0000000000021264. PubMed 32702912 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04340323
Lead sponsor
Pavol Jozef Safarik University
Responsible party
Peter Urdzik (Faculty of Medicine, Pavol Jozef Safarik University) — Principal investigator
First posted
Apr 9, 2020
Start date
May 2, 2020
Primary completion
Dec 1, 2021
Completion
Jan 26, 2022
Last update
Mar 2, 2022

Study contacts

Peter Urdzik, prof.MD,PhD
principal investigator · Pavol Jozef Safarik University, Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion